Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Herlystic
product3 mentionslast seen Nov 12, 2026
Investigational immunotherapy for prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma.
Relationships 13
- OS Therapies IncorporateddevelopsHerlystic99% confidence3 sources
- Herlysticapplies tometastatic osteosarcoma treatment96% confidence1 source
- Herlysticconforms toRare Pediatric Disease designation95% confidence1 source
- Herlysticconforms toFast Track Designation95% confidence1 source
- Herlysticconforms toOrphan Drug designation95% confidence1 source
- Herlysticapplies toosteosarcoma treatment93% confidence1 source
- Herlysticapplies toosteosarcoma prevention and recurrence reduction93% confidence1 source
- Herlysticconforms toRare Pediatric Disease priority review voucher program92% confidence1 source
- U.S. Food and Drug AdministrationapprovesHerlystic88% confidence2 sources
- European Medicines AgencyapprovesHerlystic88% confidence2 sources
- U.K. Medicines and Healthcare products Regulatory AuthorityapprovesHerlystic75% confidence1 source
- Australian Therapeutic Goods AdministrationapprovesHerlystic75% confidence1 source
- Medicines and Healthcare products Regulatory AgencyapprovesHerlystic50% confidence1 source
Relationship
European Medicines AgencyapprovesHerlystic
88% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 19, 2026OS Therapies Inc 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Conditional Marketing Authorisation Applications (CMAAs) to the European Medicines Agency (EMA)
- filingSEC EDGAROct 5, 2026OS Therapies Inc 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company has described plans to pursue a U.S. Biologics License Application (BLA) under the Accelerated Approval pathway and a CMAA in Europe